| pubmed-article:19662347 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19662347 | lifeskim:mentions | umls-concept:C0011923 | lld:lifeskim |
| pubmed-article:19662347 | lifeskim:mentions | umls-concept:C0020456 | lld:lifeskim |
| pubmed-article:19662347 | lifeskim:mentions | umls-concept:C0032743 | lld:lifeskim |
| pubmed-article:19662347 | lifeskim:mentions | umls-concept:C0237881 | lld:lifeskim |
| pubmed-article:19662347 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:19662347 | lifeskim:mentions | umls-concept:C0750502 | lld:lifeskim |
| pubmed-article:19662347 | lifeskim:mentions | umls-concept:C1706089 | lld:lifeskim |
| pubmed-article:19662347 | lifeskim:mentions | umls-concept:C0205191 | lld:lifeskim |
| pubmed-article:19662347 | lifeskim:mentions | umls-concept:C0205478 | lld:lifeskim |
| pubmed-article:19662347 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:19662347 | pubmed:dateCreated | 2009-9-18 | lld:pubmed |
| pubmed-article:19662347 | pubmed:abstractText | The purpose of this study was to evaluate the adverse effects of chronic marked hyperglycemia on clinical diagnostic performance of positron emission tomography (PET) using (18)F-fuorodeoxyglucose (FDG). | lld:pubmed |
| pubmed-article:19662347 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19662347 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19662347 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19662347 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19662347 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19662347 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19662347 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:19662347 | pubmed:issn | 1864-6433 | lld:pubmed |
| pubmed-article:19662347 | pubmed:author | pubmed-author:NakamotoYujiY | lld:pubmed |
| pubmed-article:19662347 | pubmed:author | pubmed-author:SagaTsuneoT | lld:pubmed |
| pubmed-article:19662347 | pubmed:author | pubmed-author:TogashiKaoriK | lld:pubmed |
| pubmed-article:19662347 | pubmed:author | pubmed-author:HigashiTatsuy... | lld:pubmed |
| pubmed-article:19662347 | pubmed:author | pubmed-author:IshimoriTakay... | lld:pubmed |
| pubmed-article:19662347 | pubmed:author | pubmed-author:KawashimaHide... | lld:pubmed |
| pubmed-article:19662347 | pubmed:author | pubmed-author:MatsumotoKeii... | lld:pubmed |
| pubmed-article:19662347 | pubmed:author | pubmed-author:IshizuKoichiK | lld:pubmed |
| pubmed-article:19662347 | pubmed:author | pubmed-author:HaraTadashiT | lld:pubmed |
| pubmed-article:19662347 | pubmed:author | pubmed-author:KawaseShigeto... | lld:pubmed |
| pubmed-article:19662347 | pubmed:author | pubmed-author:SugaTsuyoshiT | lld:pubmed |
| pubmed-article:19662347 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19662347 | pubmed:volume | 23 | lld:pubmed |
| pubmed-article:19662347 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19662347 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19662347 | pubmed:pagination | 657-69 | lld:pubmed |
| pubmed-article:19662347 | pubmed:meshHeading | pubmed-meshheading:19662347... | lld:pubmed |
| pubmed-article:19662347 | pubmed:meshHeading | pubmed-meshheading:19662347... | lld:pubmed |
| pubmed-article:19662347 | pubmed:meshHeading | pubmed-meshheading:19662347... | lld:pubmed |
| pubmed-article:19662347 | pubmed:meshHeading | pubmed-meshheading:19662347... | lld:pubmed |
| pubmed-article:19662347 | pubmed:meshHeading | pubmed-meshheading:19662347... | lld:pubmed |
| pubmed-article:19662347 | pubmed:meshHeading | pubmed-meshheading:19662347... | lld:pubmed |
| pubmed-article:19662347 | pubmed:meshHeading | pubmed-meshheading:19662347... | lld:pubmed |
| pubmed-article:19662347 | pubmed:meshHeading | pubmed-meshheading:19662347... | lld:pubmed |
| pubmed-article:19662347 | pubmed:meshHeading | pubmed-meshheading:19662347... | lld:pubmed |
| pubmed-article:19662347 | pubmed:meshHeading | pubmed-meshheading:19662347... | lld:pubmed |
| pubmed-article:19662347 | pubmed:meshHeading | pubmed-meshheading:19662347... | lld:pubmed |
| pubmed-article:19662347 | pubmed:meshHeading | pubmed-meshheading:19662347... | lld:pubmed |
| pubmed-article:19662347 | pubmed:meshHeading | pubmed-meshheading:19662347... | lld:pubmed |
| pubmed-article:19662347 | pubmed:meshHeading | pubmed-meshheading:19662347... | lld:pubmed |
| pubmed-article:19662347 | pubmed:meshHeading | pubmed-meshheading:19662347... | lld:pubmed |
| pubmed-article:19662347 | pubmed:meshHeading | pubmed-meshheading:19662347... | lld:pubmed |
| pubmed-article:19662347 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19662347 | pubmed:articleTitle | Significance of chronic marked hyperglycemia on FDG-PET: is it really problematic for clinical oncologic imaging? | lld:pubmed |
| pubmed-article:19662347 | pubmed:affiliation | Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. | lld:pubmed |
| pubmed-article:19662347 | pubmed:publicationType | Journal Article | lld:pubmed |
